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s u m m a r y 
Background: Brain abscess is an uncommon condition, but carries high mortality. Current treatment 
guidelines are based on limited data. Surveillance of clinical, radiological and microbiology data is im- 
portant to inform patient stratification, interventions, and antimicrobial stewardship. 
Methods: We undertook a retrospective, observational study of patients with brain abscess, based on 
hospital coding, in a UK tertiary referral teaching hospital. We reviewed imaging data, laboratory micro- 
biology, and antibiotic prescriptions. 
Results: Over a 47 month period, we identified 47 adults with bacterial brain abscess (77% male, median 
age 47 years). Most of the abscesses were solitary frontal or parietal lesions. A microbiological diag- 
nosis was secured in 39/47 (83%) of cases, among which the majority were of the Streptococcus milleri 
group (27/39; 69%), with a predominance of Streptococcus intermedius (19/27; 70%). Patients received a 
median of 6 weeks of intravenous antibiotics (most commonly ceftriaxone), with variable oral follow-on 
regimens. Ten patients (21%) died, up to 146 days after diagnosis. Mortality was significantly associated 
with increasing age, multiple abscesses, immunosuppression and the presence of an underlying cardiac 
anomaly. 
Conclusion: Our data suggest that there has been a shift away from staphylococcal brain abscesses, to- 
wards S. intermedius as a dominant pathogen. In our setting, empiric current first line therapy with cef- 
triaxone remains appropriate on microbiological grounds and narrower spectrum therapy may sometimes 
be justified. Mortality of this condition remains high among patients with comorbidity. Prospective stud- 
ies are required to inform optimum dose, route and duration of antimicrobial therapy. 
© 2020 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. 






















Brain abscesses are a focal infection characterised by a walled-
ff collection of pus within the brain parenchyma. They may arise
pontaneously, or as a result of specific risk factors including intra-
enous drug use, congenital cardiac defects, infective endocarditis,
mmunosuppression, or a contiguous focus of infection spreading
irectly to the adjacent central nervous system (CNS), for example∗ Corresponding author at: Department of Infectious Diseases and Microbiology, 
xford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Heading- 
on, Oxford OX3 9DU, UK. 






163-4453/© 2020 The Author(s). Published by Elsevier Ltd on behalf of The British Infec
 http://creativecommons.org/licenses/by/4.0/ ) rom dental, sinus, and middle or inner ear infection. 1–5 Previous
eports suggest that brain abscesses predominantly occur in males
accounting for around 70% of cases) and affect young adults. 6 , 7 
Brain abscesses are usually caused by bacteria, although can
lso be caused by other pathogens including fungi and proto-
oa. 4 Prior to 1960, staphylococcal infection was the commonest
eported cause, accounting for over a third of cases, with strep-
ococci accounting for around a further 30%. 6 However, in recent
ecades, the incidence of staphylococcal brain abscesses has been
alling, with streptococci increasingly dominating. 6 , 7 Organisms in
he Streptococcus milleri group are frequent commensals of the
ropharynx and gastrointestinal tract. They are well recognised fortion Association. This is an open access article under the CC BY license. 
























































































































a propensity to cause abscesses, and are a recognised cause of cen-
tral nervous system infections. 8 , 9 The S. milleri group includes S.
constellatus, S. anginosus and S. intermedius , and can also be classi-
fied by phenotypic identification as ‘microaerophilic streptococci’,
reflecting their optimum conditions for growth in partial pressures
of oxygen that are lower than atmospheric O 2. 
8 , 10 Pathogenesis
is mediated by β-haemolysis and production of extracellular en-
zymes such as hyaluronidase and DNAase. 8 , 11–13 
Anaerobes are also described as important contributors to
brain abscesses, and polymicrobial aetiology has been described in
around a quarter of cases. However, evidence for the presence of
anerobes is limited, as studies before 2010 report identification of
a pathogen in only approximately 60% of cases, 14 , 15 and even with
improved approaches to diagnosis, sensitivity of laboratory diagno-
sis may be limited for anaerobic organisms. With modern stereo-
tactic neurosurgical sampling methods and advances in molecular
diagnostics, there is scope for improving rates of identification of
specific pathogens, up to ∼80% in the more recent literature, 7 pro-
viding an opportunity to review approaches to antimicrobial ther-
apy. 
There are no recent unifying international or national guide-
lines for the management of bacterial brain abscesses. An ‘Infection
in Neurosurgery Working Party’ published antibiotic recommenda-
tions on behalf of the British Society of Antimicrobial Chemother-
apy in 20 0 0. 16 However, these recommendations were based on
limited published data, and are not universally adopted in clinical
practice. Other recommendations are made elsewhere in the exist-
ing literature, including the need to rule out other causes of space-
occupying lesions (such as primary or metastatic malignancy), and
additional investigations including an HIV test and consideration
of cardiac echocardiography. 4 , 5 , 17 The recommended empirical an-
timicrobial treatment for brain abscesses is often intravenous cef-
triaxone or cefotaxime, 5 , 18 which cover the likely gram-positive
causes, as well as providing coverage for the less common gram
negative organisms, and offering sufficient central nervous system
penetration. Adjunctive metronidazole may also be recommended
to cover anaerobic organisms. 16 Despite the microaerophilic na-
ture of S milleri , metronidazole is largely ineffective against this
group. 19 
However, the suggested choice, duration and route of antibi-
otic therapy is based on scarce evidence. 20 In the current era
of increasing antimicrobial resistance, careful scrutiny of labora-
tory data is required to ensure that empiric treatment regimens
are sufficiently broad to cover the majority of likely pathogens,
while at the same time considering antimicrobial stewardship
to limit unnecessary exposure to broad-spectrum agents. Fur-
thermore, new evidence for endocarditis and for musculoskele-
tal infection suggests that oral antibiotics are non-inferior to par-
enteral therapy in some deep-seated infections. 21 , 22 At present
there are no such data to inform the management of CNS infec-
tion, but the route of therapy remains an important question to be
addressed. 
Given this changing landscape of antimicrobial therapy, the
paucity of epidemiological data, and the limited guidelines for
brain abscesses, we set out to collect clinical and laboratory data
from a large UK teaching hospital to examine the epidemiological
and microbiological trends of bacterial brain abscesses. We specif-
ically undertook to investigate: i) Evidence for changes in the epi-
demiology or microbiology of brain abscesses over time; ii) The
extent to which antimicrobial prescribing was adherent to local
guidelines; iii) The extent to which current antimicrobial manage-
ment strategies are appropriate to cover the organisms identified,
considering both empirical and directed therapy; iv) Determination
of any host factors that are associated with specific outcomes, in
order to identify high risk cases, with implications for prognosis,
monitoring and interventions. ethods 
ata collection 
We collected data retrospectively from the electronic patient
ecords of Oxford University Hospitals (OUH) NHS Foundation
rust, a large teaching hospital trust in the Thames Valley region
f the UK and a tertiary referral centre for neurosurgery. We iden-
ified patients using coding data (any patients coded with ‘G06.0 ′ ,
he ICD code for ‘Intracranial abscess and granuloma’) admitted be-
ween 1st January 2013 and 1st December 2016. We screened indi-
idual records to remove paediatric cases, erroneously coded cases
nd those with non-bacterial causes (e.g. Toxoplasma gondii ), and
hen reviewed electronic notes and results, extracting the relevant
ata. The study was undertaken as a registered audit to determine
he quality of management of brain abscesses. Approval for this
as given internally via the OUH audit management team and we
ollected and stored data in accordance with relevant governance
tandards. All data were anonymised prior to analysis. 
adiology data 
Brain abscesses in our cohort were typically diagnosed by com-
uter topography (CT) scan, in some cases followed by magnetic
esonance imaging (MRI) to delineate further. We collected radiol-
gy data for the definitive pre-treatment scan only, as subsequent
equential scans varied according to clinical need. For the purposes
f data collection for our study, all scans were retrospectively re-
iewed by two independent radiologists, blinded to all other clin-
cal and microbiological data. To calculate the size of an abscess
n cross-section, we assumed an elliptical area (area (mm 3 ) = 0.5 x
aximum width (mm) x 0.5 x maximum length (mm) x π ). 
aboratory diagnosis 
Samples collected from a brain abscess would typically be
ransported to the microbiology laboratory on an urgent basis, and
ulture plates are set up promptly on receipt in the laboratory by
iomedical Scientists staffing a 24-hour service. Microbiology diag-
ostic work was undertaken in our ISO approved clinical diagnos-
ic laboratory. Methods were based on National Standard Methods
PHE). 23 In brief, samples from brain abscesses were handled as
ollows: a Gram stain was undertaken and the sample was inocu-
ated into (i) cooked meat enrichment broth (extended incubation
or 10 days in aerobic conditions), (ii) blood, chocolate and MacK-
nkey agar incubated in 5% CO 2 , (iii) blood, NAT and neomycin
gar (in anaerobic conditions with metronidazole discs). All were
ncubated at 35–37 °C. Growth on any plate was followed up by
dentification using by mass spectrometry (Maldi-TOF). Antibiotic
usceptibility was determined on the automated Phoenix platform
Becton Dickinson). Examination for additional specific pathogens
ould be undertaken at the request of the clinical team or based
n attributes of the patient’s background or presenting features
e.g. mycobacteria, nocardia, fungi, acanthamoeba). 
For streptococci, susceptibility to penicillin was further inves-
igated by determination of the minimum inhibitory concentra-
ion (MIC) based on the breakpoint defined by the European Com-
ittee on Antimicrobial Susceptibility Testing (EUCAST) using both
hoenix and an MIC strip (ETEST; Biomérieux); the breakpoints are
0.25 mg/L for benzylpenicillin and ≤0.5 mg/L for amoxicillin. 24 
Blood cultures were inoculated into BACTEC bottles under asep-
ic technique and incubated on the Becton Dickinson BACTEC FX
ystem, using a standard operating procedure based on SMI B 37:
investigation of blood cultures’. 25 









































































































a  ntimicrobial therapy guidelines 
We audited each case for adherence to local antimicrobial
uidelines, which are accessible to clinical staff via intranet and
he smartphone app ‘Microguide’ ( http://www.microguide.eu/ ). For
acterial brain abscesses, antimicrobial advice in our setting is as
ollows: 
• Urgent biopsy with collection of specimens for culture is rec-
ommended in most cases; 
• Empiric choice of antimicrobial therapy is ceftriaxone (2 g iv bd)
and metronidazole (400 mg tds po); 
• For empiric regimens, the cephalosporin should be substituted
with ciprofloxacin in patients with beta-lactam allergy, and
vancomycin should be added in cases known to be colonised
or infected with meticillin resistant Staphylococcus aureus ; 
• For patients at risk of immunosuppression, empiric therapy
may be amended to broaden spectrum of cover; 
• Initial empiric treatment should be amended according to cul-
ture and susceptibility data; 
• The microbiology/infectious diseases team should be consulted
for clinical review and advice; 
• Treatment is recommended for 4–8 weeks. 
ata regarding surgical and medical management 
A limited dataset regarding surgical intervention and antimicro-
ial therapy was collected from the electronic patient record. An-
imicrobial therapy was monitored and modified under supervision
f the Infectious Diseases / Microbiology team according to the
linical context and microbiology results. For patients well enough
o be discharged but requiring ongoing parenteral therapy, the full
ourse of antibiotics was administered under the supervision of the
xford outpatient antimicrobial therapy (OPAT) team via a periph-
rally inserted central catheter (PICC). 26 
tatistical methods 
Descriptive statistics of the data was collated using Microsoft
xcel and SPSS software packages. Univariate associations were ex-
lored using Fisher’s Exact Test, one-way ANOVA or Kruskal-Wallis
tatistical tests, depending on the modality and distribution of the
ata. 
esults 
rain abscess patients presented to our service at an average rate of 
 per month and were predominantly male 
Over the study time period of 47 months, 74 patients were
oded by the hospital as G06.0. Of these, 47 were aged ≥16 years
nd had a final diagnosis of a bacterial brain abscess ( Table 1 ;
uppl Fig 1 ). All the data reported in this study are provided as a
etadata table in .xlsx format (see link in supplementary data sec-
ion). The majority of our cases were male ( n = 36; 77%), in keeping
ith previous case series. 14 , 15 The median age was 47 years (range
7–91). 
An identifiable risk factor for brain abscesses was identified in
6 (55%; Fig 1 A; Table 1 ). Sinus involvement was identified in 7/47
ases (15%; Table 2 ). Examples of the anatomical relationship be-
ween sinus infection and brain abscess are shown in Fig 2 , and
etailed radiological findings for all cases are included in the sup-
lementary metadata table. HIV testing was not consistently un-
ertaken, being reported for only 30/47 cases (64%), all of which
ere negative. rain abscesses were typically single lesions caused by streptococcus 
ntermedius 
The majority of abscesses were a single lesion ( n = 36; 77%),
ommonest sites were frontal ( n = 15; 32%) and parietal ( n = 8;
7%); Table 2 . Microbiological diagnosis was made in 39/47 cases
83%; Table 3 ), of which 34 were cultured from pus and five
rom blood cultures. Strikingly, organisms of the S. milleri group
ere present in 29/39 cases in which diagnostic data were avail-
ble (74%), among which S. intermedius accounted for the major-
ty (19/29; 66%; Fig 1 B). In one case, S. milleri was identified from
n orbital swab that had been collected in another clinical centre.
lthough the result of a swab should be interpreted with caution
s potentially reflecting only colonising or commensal flora, in this
ase the growth of S. milleri is a plausible agent of deep-seated in-
ection. Polymicrobial infection was identified in five cases, among
hich two involved organisms from the S. milleri group ( Table
 ). among the 29 S. milleri isolates, all were penicillin susceptible
confirmed by a recorded breakpoint in 18 cases, and by direct disc
esting in 11; see supplementary metadata table for MIC values).
mongst the 6 anaerobic isolates, all were metronidazole sensitive.
treptococcus intermedius was associated with larger abscesses 
We investigated whether the presence of S. milleri was associ-
ted with any clinical or radiological characteristics and identified
 significant relationship only with the size of the abscess (median
ross-sectional size of abscess 930mm 3 for S. milleri vs 190mm 3 for
ther organisms; p = 0.0 0 05; Suppl Table 1 ). 
eurosurgical drainage was undertaken in the majority of cases 
Among our 47 patients, 38 (81%) had an intervention to drain
he abscess, and 15 underwent > 1 drainage procedure (Suppl Table
 ). The median time between admission for the brain abscess and
rst procedure (where first microbiological samples were taken)
as 1 day (range 0–10 days). One individual had an elective biopsy
or a presumed tumour. When the microbiology and histology sug-
ested a diagnosis of a brain abscess, the patient was re-admitted
or antibiotic treatment. 
ntibiotic treatment was undertaken for a median of six weeks 
All patients were treated with intravenous antibiotics, predom-
nantly using our local recommended first line antibiotic choice of
eftriaxone (used with or without metronidazole) in 39/47 cases
83%). Alternative choices justified on the grounds of clinical con-
ext and/or specific susceptibility results, with expert input based
n review by our clinical infection/microbiology teams (specific
rescriptions and rationale for choices are listed in Table 4 ). We
id not identify any cases in which there was a deviation from lo-
al prescribing protocols. Duration of IV therapy was most com-
only 6 weeks while follow-on oral therapy varied from 2–8
eeks (Suppl Fig 2 ). 
rain abscesses are associated with high mortality 
Ten patients in this cohort died (21%). Five (50%) deaths oc-
urred before completion of the primary antimicrobial course and
ere directly attributable to the brain abscess (median 9 days af-
er presentation; range 1–50 days), three were after the completion
f treatment but showed possible attribution to brain abscess (me-
ian time post-presentation 116 days; range 76–146 days). One was
ttributed to unrelated comorbidities (113 days post-presentation),
nd one died at another centre with no further data available
626 Microbial aetiology of brain abscess / Journal of Infection 80 (2020) 623–629 
Table 1 
Demographic and host characteristics of a brain abscess cohort of 47 adults recruited in a UK tertiary 
referral hospital in the UK. sd = standard deviation; IQR = inter-quartile range. 
Demographics Male Female Total 
Total number of patients (%) 36 (76.6) 11 (23.4) 47 (100) 
Median age at presentation (sd) 46.6 (15.8) 63.0 (20.5) 46.9 (16.9) 
Range of age at presentation (years) (IQR) 17–89 (38–59) 23–91 (41–64) 17–91 (38–61) 
Mortality (%) 6/36 (16.7) 4/11 (36.4) 10/47 (21.3) 
Risk Factors ∗: 
Intravenous Drug Use (%) 5/36 (13.9) 2/11 (18.2) 7/47 (14.9) 
Immunosuppression ∗∗(%) 1/36 (2.8) 1/11 (9.1) 2/47 (4.6) 
Cardiac Anomaly (%) 7/36 (19.4) 1/11 (9.1) 8/47 (17.0) 
Dental / ENT source (%) 10/36 (27.8) 4/11 (36.4) 14/47 (29.8) 
No risk factor identified (%) 17/36 (47.2) 4/11 (36.4) 21/47 (44.7) 
∗ Some individuals have > 1 risk factor(s). 
∗∗ No patients were HIV positive (among n = 30 who received a test) . 
Fig. 1. Summary of predisposing factors and underlying microbiology amongst 47 patients with brain abscess. A: Proportion of patients with and without predisposing 
factors, and a breakdown of the overlap between these factors. ENT = ears, nose and throat, including sinus infection. B: Culture results, showing predominance of S. milleri 




































m  (146 days post-presentation). Of the 10 deaths, seven had signif-
icant medical comorbidities, including immunosuppression ( n = 2),
cardiac disease ( n = 3), and other underlying medical conditions
( n = 5). 
Increasing age, immunosuppression, and the presence of an un-
derlying cardiac anomaly were significantly associated with mor-
tality on univariate analysis ( p = 0.005, p = 0.04, p = 0.03, respec-
tively; ( Table 5 ). Mortality was not significantly associated with




In this UK cohort of brain abscess patients, we found a low
prevalence of Staphylococcal infection and a predominance of
Streptococcal species, in particular S. intermedius of the S. milleri
group. We identified a pathogen in 83% of cases, which is compa-
rable to another recent UK case series 7 and compares favourably
with two other data sets in which < 60% of cases had a microbio-ogical diagnosis. 14 , 15 Improvements in sampling techniques, espe-
ially with relation to the timing of initial antibiotics, together with
dvances in microbiological laboratory practice (including the use
f the MALDI-TOF) are likely reasons for the increased rates of lab-
ratory diagnosis. Current expansion of metagenomic approaches
o replace or supplement traditional phenotype-based methods
7 , 28 may underpin future improvements in identification rates. 
The dominance of S. milleri species is consistent with other
ublished UK epidemiological datasets on causative microbiology
 , 14 , 29 and temporal trends in brain abscess epidemiology. 6 The
ominant role of S. intermedius is also exemplified by case reports
f brain abscesses 30–34 and noted to be a frequent species in the
. milleri group isolated from central nervous system specimens. 35 
nother recent UK case series suggests the ‘ S. anginosus group’ is
redominant, but does not provide a breakdown of the S. milleri
roup by species. 7 It is unclear how important speciation within
he S milleri group is in clinical practice, given the entire group
ends to be penicillin sensitive. S. intermedius may be dominant
n brain abscesses as a result of its ecological niche in dental, si-
us and ear infections. 36 Its particular tendency to form abscesses
ay relate to the presence of specific virulence factors, including
Microbial aetiology of brain abscess / Journal of Infection 80 (2020) 623–629 627 
Table 2 
Radiological features of brain abscesses at time of presentation. 
Features of abscess Number (%) 
Number of abscesses 
Single 36/47 (77%) 
Multiple 11/47 (23%) 
Size of abscess 
Median cross-sectional size of abscess, mm 2 (IQR) 500 (199–889) 
Location of abscess(es): 
Frontal 15/47 (32%) 
Parietal 8/47 (17%) 
Temporal 7/47 (15%) 
Occipital 4/47 (9%) 
Cerebellum 2/47 (4%) 
Other subcortical location 2/47 (4%) 
Multiple locations 9/47 (19%) 
Radiological features: 
Abscess wall enhancement 42/44 ∗ (95%) 
Dual Rim Sign present 10/44 ∗ (23%) 
Oedema present in one lobe 31/47 (66%) 
Oedema present in > 1 lobe 15/47 (32%) 
Ventriculitis present 5/47 (11%) 
Sinus involvement 7/47 (15%) 




















Fig. 2. Neuro-imaging to demonstrate the anatomical relationship between sinus 
infection and brain abscess. A: Coronal high resolution CT image (shows left- 
sided otomastoiditis with focal breach of the bony roof of the mastoid. B: Coronal, 
gadolinium enhanced T1-weighted image, performed in the same patient 10 days 
after the CT scan, shows a small cerebral abscess inferiorly in the left temporal 
lobe adjacent to the infected mastoid (for panels A and B, patient ID: BA04). C: In 
a different patient, an axial, gadolinium enhanced T1-weighted image demonstrates 
a left frontal brain abscess secondary to adjacent left frontal sinusitis with focal 







r  nzymes that digest host tissue (such as sialidase, hyaluronidase,
nd human-specific cytolysin), 37 and factors that enhance binding
o fibronectin and laminin in the extra-cellular matrix. 38 This is in
eeping with the significantly larger size of abscesses we found in
ssociation with these organisms. 
Another striking finding from the microbiological data is the
elative lack of staphylococcal infections. A recent systematic re-
iew reported staphylococci as still causing approximately 20% of
rain abscesses, 6 but S. aureus was found in < 10% of cases in an-
ther recent UK series, 7 and we identified only one case caused by
. aureus . 
The small number of identified anaerobic infections (6/47,
2.8%) in our cohort is consistent with previous literature, includ-
ng a systematic review reporting identification of anaerobes in ap-
roximately 10% of cases. 6 , 15 , 39 This may be partly reflective of the
ifficulty in culturing anaerobes, particularly if sample transport
o the laboratory is delayed. We did not collect specific data to
etermine whether any delays arose in this sample set, so wereTable 3 
Pathogens identified in a cohort of 47 adults with a diagnosis of brain abscess. 
Causative Organism 
Gram positive infections 
Streptococcus intermedius a , b 
Streptococcus constellatus a , b 
Streptococcus anginosis a 
Streptococcus milleri group (not further identified) c 
Staphylococcus aureus d 
Listeria monocytogenes e 
Gram negative or mixed infections 
E. coli + Staphlyococcus epidermidis 
Pseudomonas aeruginosa 
Fusobacterium nucleatum f 
Citrobacter, Pseudomonas, Corynebacterium + anaerobes 
Aggregatibacter aphrophilus + Actinomyces meyeri 
No organism identified 
Sterile sample 
No sample taken 
a These organisms are all part of the S. milleri group. 
b One S. intermedius and one S. constellatus reported in mixed culture with anaero
c Isolate grown from an orbital swab. 
d S. aureus sensitive to meticillin. 
e Both patients with Listeria infection were > 55 years of age but neither had any 
f Of the three cases with anaerobes isolated as a sole causative organism, two patinable to investigate this point specifically. The accumulation of
arger data sets of microbiological data based on molecular testing
s needed to determine the contribution of anaerobes to intracra-
ial abscesses. 
ntibiotic therapy 
Our data demonstrate that ceftriaxone with metronidazole cur-
ently remains a safe empiric antimicrobial regimen in our set-Number of cases (%) Ceftriaxone Sensitivity 
20 (43%) 20/20 (100%) 
4 (9%) 4/4 (100%) 
4 (8.5%) 4/4 (100%) 
1 (17.0%) 1/1 (100%) 
1 (2.1%) 1/1 (100%) 
2 (4.3%) 0/2 (0%) 
1 (2.1%) 1/1 (100%) 
1 (2.1%) 0/1 (0%) 
3 (6.4%) N/A 
1 (2.1%) 0/1 (0%) 
1 (2.1%) 1/1 (100%) 
4 (8.5%) N/A 
4 (8.5%) N/A 
bes. 
known cause of immunosuppression. 
ents were intravenous drug users and the third had no clear identified source. 
628 Microbial aetiology of brain abscess / Journal of Infection 80 (2020) 623–629 
Table 4 
Intravenous and oral antibiotic regimens used to treat 46 adults with bacterial brain abscess. Data missing for one patient in cohort of 47. 
Antibiotic agent(s) Number (%) Rationale for deviation from protocol for intravenous antibiotics (ceftriaxone) 
Intravenous therapy 
Ceftriaxone monotherapy 5 (14.7%) N/A 
Ceftriaxone + metronidazole 34 (72.3%) N/A 
Amoxicillin + gentamicin 2 (4.3%) L. monocytogenes infection 
Ceftazidime monotherapy 1 (2.1%) P. aeruginosa infection 
Ceftazidime + metronidazole 1 (2.1%) No organism identified, but healthcare acquired so risk of P. aeruginosa 
Flucloxacillin 1 (2.1%) Methicillin sensitive S. aureus infection 
Meropenem monotherapy 1 (2.1%) No organism identified, but patient immunosuppressed 
Meropenem + vancomycin 1 (2.1%) Mixed antibiotic-resistant organisms (potential AmpC-carrying Citrobacter species, Pseudomonas 
aeruginosa and penicillin resistant Corynebacterium) 
ORAL THERAPY 
None 25 (53.2%) N/A 
Co-amoxiclav 7 (14.9%) N/A 
Amoxicillin 5 (10.6%) N/A 
Clindamycin 2 (4.3%) N/A 
Ciprofloxacin 2 (4.3%) N/A 
Died before oral switch 5 (10.6%) N/A 
N/A = not applicable . 
Table 5 
Associations between clinical features and mortality in a cohort of 47 adults with bacterial brain abscess. 
Characteristic Died ( n = 10) Survived ( n = 37) p -value a (univariate) 
Median Age (IQR) 60 (47 – 77) 46 38 – 61 0.005 
Sex (proportion male) 6/10 (60%) 30/37 (81%) 0.16 
Intravenous Drug Use 2/10 (20%) 5/37 (14%) 0.61 
Cardiac Anomaly 4/10 (40%) 4/37 (11%) 0.03 
Immunosuppressed b 2/10 (20%) 0/37 (0%) 0.04 
Dental/ENT Source 3/10 (30%) 11/37 (30%) 0.99 
Any risk factor present 8/10 (80%) 18/37 (49%) 0.15 
Mean number of brain abscesses 1.89 1.35 < 0.001 
≥1 abscess present 4/10 (40%) 7/37 (19%) 0.21 
Median cross-sectional size of abscess, mm 2 (IQR) 707 (186–1272) 478 (236–865) 0.26 
Aspiration/drainage undertaken 7/10 (70%) 31/37 (84%) 0.33 
More than one aspiration/drainage procedure performed 1/10 (10%) 15/37 (41%) 0.13 
Presence of microbiological diagnosis 7/10 (70%) 32/37 (86%) 0.22 
Streptococcus milleri infection 6/10 (60%) 23/37 (62%) 1.0 
Streptococcus intermedius infection 3/10 (30%) 16/27 (60%) 0.15 
Oral antibiotics received c 0/5 (0%) 19/37 (51%) 0.05 
a p-values for categorical variables calculated using Fisher’s Exact test, for continuous variables using one-way ANOVA or Kruskal-Wallis, dependent on distribution of 
the data. Bold font indicates significant p value ( < 0.05). 
b An HIV test was recorded for 30/47 cases (64%); all were negative. It is not clear from our data whether the remaining 17 were offered a test. 












































s  ting. 40 Narrower spectrum agents could be considered for the
treatment of fully sensitive streptococci when supported by lab-
oratory data but may be less easy to administer in one or two
daily doses. Furthermore, culture-based methods may not accu-
rately reflect the entire spectrum of organisms present, as evidence
emerges for a complex microbiome within abscesses. 41 A careful
risk/benefit analysis is needed for inclusion of metronidazole on
empiric grounds: an anaerobic contribution may be present even
when not confirmed by laboratory testing, but addition of metron-
idazole can cause nausea, and prolonged therapy is associated with
a risk of neuropathy. 
Four to six weeks of therapy is typically suggested for intra-
venous ceftriaxone, 5 but given the ongoing international drive to
restrict and reduce the duration and use of broad spectrum an-
tibiotics, 42 it is important to consider whether typical prolonged
parenteral antimicrobial regimens used in brain abscesses could
potentially be restricted without loss of clinical efficacy, as is the
case for other conditions, such as intra-abdominal infections, 43 en-
docarditis 22 and osteomyelitis. 21 Large randomised clinical trials
with prospective follow-up are ideally needed to address the ques-
tion about optimum route and duration of therapy, but in practice
are difficult to conduct for a rare condition. The lack of guidance
available on the choice, course and use of oral antibiotics 16 , 20 is
reflected in our findings of a wide range of choices for follow-onantibiotics and their duration. autcomes 
Despite prompt surgical drainage and prolonged courses of an-
ibiotic therapy, the mortality rate of this condition remains high,
articularly in the context of frailty (in this setting, associated with
mmunocompromise, cardiac anomalies and older age). There was
o increased mortality among patients in whom we did not se-
ure a microbiological diagnosis, suggesting that empiric therapy
s likely to be covering the underlying organisms present in this
roup. Five deaths occurred following completion of intravenous
ntibiotics in the group receiving no follow-on antibiotics; how-
ver, only one of these deaths was definitively attributable to brain
bscess, while the other four were associated with significant co-
orbidities (all had cardiac conditions and two were significantly
mmunosuppressed). 
imitations 
Our data rely upon the accuracy of diagnostic coding: just as
ome non-brain abscess cases were erroneously coded as G06.0,
ome genuine brain abscess cases may have been coded with a
ifferent ICD code. This relatively low incidence rate highlights the
ifficulties of performing interventional trials to examine conclu-
ions further, and any such trial would need to be coordinated
cross multiple centres. 














































































































Our findings apply to a specific setting in the UK and should be
xtrapolated with caution. We recognise that the tertiary nature of
ur hospital may also bias the case-mix, either as a result of over-
epresenting complex cases that need specialist multi-disciplinary
anagement, and/or by the exclusion of certain groups – includ-
ng those who are too unwell to transfer (with high mortality) and
hose with simple/limited disease who are managed in local hos-
itals without the need for referral to a specialist centre. We re-
tricted the remit of our audit to adults, and we are therefore un-
ble to extend our conclusions to brain abscesses in the paediatric
opulation. Whilst our retrospective, observational approach adds
mportant information that may help to underpin management de-
isions, there is a clear need for large prospective randomised con-
rolled trials. 
onclusion 
From this study of the diagnosis and management of brain ab-
cesses, we have provided contemporaneous UK epidemiological
ata in the context of limited published evidence. The predom-
nant pathogen currently identified in this setting is penicillin-
ensitive S. intermedius, but an emerging literature suggests a more
omplex microbiome. Multi-centre randomised prospective studies
ay be required to provide evidence underpinning the optimum
hoice, route and duration of antibiotic therapy. 
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